Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC-XR) (1200 and 2400mg/Day) as Adjunctive Therapy in Subjects With Refractory Partial Seizures Due to Epilepsy on up to Three Concomitant Antiepileptic Medications.

Trial Profile

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC-XR) (1200 and 2400mg/Day) as Adjunctive Therapy in Subjects With Refractory Partial Seizures Due to Epilepsy on up to Three Concomitant Antiepileptic Medications.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2014

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2014 Results will be published in the arch 2014 issue of Acta Neurologica Scandinavica according to a Supernus Pharmaceuticals media release. Results were also summarised in the media release.
    • 28 Apr 2012 Main efficacy and tolerability results presented at the 64th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2012 Results reporting neurological and ophthalmic adverse events presented at the 64th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top